


WE CLAIM:

1. A compound of Formula (I), or pharmaceutically acceptable salt thereof:



Formula (I)

wherein:

R^1 is $-NHR^6$ or $-NHCHR^6R^9$;

R^3 is H, $-L_2C(=O)OR^7$, $-C(=O)OL_6R^{12}$, $-C(=O)OL_2R^{12}$, $-L_2C(=O)OL_2R^{12}$, $-L_4C(=O)OL_5OH$, $-L_4R^{12}$, $-L_2C(=O)OL_4C(=O)L_2R^{12}$, $-L_2C(=O)OL_6R^{12}$, $-L_2C(=O)OL_4C(=O)OL_2R^{12}$, $-L_2C(=O)OL_4C(=O)R^{12}$, $-L_4C(=O)OL_2C(=O)R^{12}$, $-CF_2C(=O)R^7$, $-CH=CHC(=O)OL_4C(=O)R^{12}$, $-OL_2C(=O)OL_4C(=O)R^{12}$, $-OL_4C(=O)OL_2R^{12}$, $-OL_4C(=O)OL_2C(=O)R^{12}$ or $-L_2C(=O)OL_3R^{12}$;

R^4 is H, $-L_2C(=O)OR^7$, $-C(=O)OL_6R^{12}$, $-C(=O)OL_2R^{12}$, $-L_2C(=O)OL_2R^{12}$, $-L_4C(=O)OL_5OH$, $-L_4R^{12}$, $-L_2C(=O)OL_4C(=O)L_2R^{12}$, $-L_2C(=O)OL_6R^{12}$, $-L_2C(=O)OL_4C(=O)OL_2R^{12}$, $-L_2C(=O)OL_4C(=O)R^{12}$, $-L_4C(=O)OL_2C(=O)R^{12}$, $-CF_2C(=O)R^7$, $-CH=CHC(=O)OL_4C(=O)R^{12}$, $-OL_2C(=O)OL_4C(=O)R^{12}$, $-OL_4C(=O)OL_2R^{12}$, $-OL_4C(=O)OL_2C(=O)R^{12}$ or $-L_2C(=O)OL_3R^{12}$;

where when R^4 is H, then R^3 is $-L_2C(=O)OR^7$, $-C(=O)OL_6R^{12}$, $-C(=O)OL_2R^{12}$, $-L_2C(=O)OL_2R^{12}$, $-L_4C(=O)OL_5OH$, $-L_4R^{12}$, $-L_2C(=O)OL_4C(=O)L_2R^{12}$, $-L_2C(=O)OL_6R^{12}$, $-L_2C(=O)OL_4C(=O)OL_2R^{12}$, $-L_2C(=O)OL_4C(=O)R^{12}$, $-L_4C(=O)OL_2C(=O)R^{12}$, $-CF_2C(=O)R^7$, $-CF_2C(=O)OR^7$, $-C(=O)OR^7$, $-N(R^{11})_2$, $-CH=CHC(=O)OL_4C(=O)R^{12}$, $-OL_2C(=O)OL_4C(=O)R^{12}$, $-OL_4C(=O)OL_2R^{12}$, $-OL_4C(=O)OL_2C(=O)R^{12}$ or $-L_2C(=O)OL_3R^{12}$;

or when R^3 is H, then R^4 is $-L_2C(=O)OR^7$, $-C(=O)OL_6R^{12}$, $-C(=O)OL_2R^{12}$, $-L_2C(=O)OL_2R^{12}$, $-L_4C(=O)OL_5OH$, $-L_4R^{12}$, $-L_2C(=O)OL_4C(=O)L_2R^{12}$, $-L_2C(=O)OL_6R^{12}$, $-L_2C(=O)OL_4C(=O)OL_2R^{12}$, $-L_2C(=O)OL_4C(=O)R^{12}$, $-L_4C(=O)OL_2C(=O)R^{12}$, $-CF_2C(=O)R^7$, $-CF_2C(=O)OR^7$, $-C(=O)OR^7$, $-N(R^{11})_2$, $-CH=CHC(=O)OL_4C(=O)R^{12}$, $-OL_2C(=O)OL_4C(=O)R^{12}$, $-OL_4C(=O)OL_2R^{12}$, $-OL_4C(=O)OL_2C(=O)R^{12}$ or $-L_2C(=O)OL_3R^{12}$;

L_1 is $-(CH_2)_m-$;

L_2 is $-(CH_2)_m-$;

L_3 is $-(CH_2)_m-$;

L_4 is $-(CH_2)_m-$;

5 L_5 is $-(CH_2)_m-$;

L_6 is $-(CH_2)_mO(CH_2)_m-$;

L_9 is $-(CH_2)_m-$;

R^6 is $-C_4-C_6$ alkyl;

R^7 is $-C_1-C_3$ alkyl;

10 R^9 is L_1OH ;

each R^{11} is independently selected from H or $-C_1-C_3$ alkyl;

R^{12} is

a) $-N(R^{11})_2$;

15 b) an unsubstituted 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O;

c) a 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O substituted with $=O$;

d) a 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O substituted with C_1-C_3 alkyl or $-C(=O)OR^7$;


20 or

e) an unsubstituted phenyl;

and

each m is independently selected from 1, 2, 3, and 4.

2. The compound of Formula (I) of claim 1, or pharmaceutically acceptable salt thereof:



Formula (I)

wherein:

R^1 is $-NHR^6$ or $-NHCHR^6R^9$;

30 R^3 is H, $-L_2C(=O)OR^7$, $-C(=O)OL_6R^{12}$, $-C(=O)OL_2R^{12}$, $-L_2C(=O)OL_2R^{12}$, $-L_4C(=O)OL_5OH$, $-L_4R^{12}$, $-L_2C(=O)OL_4C(=O)L_2R^{12}$, $-L_2C(=O)OL_6R^{12}$, $-L_2C(=O)OL_4C(=O)OL_2R^{12}$, $-L_2C(=O)OL_4C(=O)R^{12}$, $-L_4C(=O)OL_2C(=O)R^{12}$, $-CF_2C(=O)R^7$, $-CH=CHC(=O)OL_4C(=O)R^{12}$, $-OL_2C(=O)OL_4C(=O)R^{12}$, $-OL_4C(=O)OL_2R^{12}$, $-OL_4C(=O)OL_2C(=O)R^{12}$ or $-L_2C(=O)OL_3R^{12}$;

R^4 is H, $-L_2C(=O)OR^7$, $-C(=O)OL_6R^{12}$, $-C(=O)OL_2R^{12}$, $-L_2C(=O)OL_2R^{12}$, $-L_4C(=O)OL_5OH$, $-L_4R^{12}$, $-L_2C(=O)OL_4C(=O)L_2R^{12}$, $-L_2C(=O)OL_6R^{12}$, $-L_2C(=O)OL_4C(=O)OL_2R^{12}$, $-L_2C(=O)OL_4C(=O)R^{12}$, $-L_4C(=O)OL_2C(=O)R^{12}$, $-CF_2C(=O)R^7$, $-CH=CHC(=O)OL_4C(=O)R^{12}$, $-OL_2C(=O)OL_4C(=O)R^{12}$, $-OL_4C(=O)OL_2R^{12}$, $-OL_4C(=O)OL_2C(=O)R^{12}$ or $-L_2C(=O)OL_3R^{12}$;

where when R^4 is H, then R^3 is $-L_2C(=O)OR^7$, $-C(=O)OL_6R^{12}$, $-C(=O)OL_2R^{12}$, $-L_2C(=O)OL_2R^{12}$, $-L_4C(=O)OL_5OH$, $-L_4R^{12}$, $-L_2C(=O)OL_4C(=O)L_2R^{12}$, $-L_2C(=O)OL_6R^{12}$, $-L_2C(=O)OL_4C(=O)OL_2R^{12}$, $-L_2C(=O)OL_4C(=O)R^{12}$, $-L_4C(=O)OL_2C(=O)R^{12}$, $-CF_2C(=O)R^7$, $-CH=CHC(=O)OL_4C(=O)R^{12}$, $-OL_2C(=O)OL_4C(=O)R^{12}$, $-OL_4C(=O)OL_2R^{12}$, $-OL_4C(=O)OL_2C(=O)R^{12}$ or $-L_2C(=O)OL_3R^{12}$;

or when R^3 is H, then R^4 is $-L_2C(=O)OR^7$, $-C(=O)OL_6R^{12}$, $-C(=O)OL_2R^{12}$, $-L_2C(=O)OL_2R^{12}$, $-L_4C(=O)OL_5OH$, $-L_4R^{12}$, $-L_2C(=O)OL_4C(=O)L_2R^{12}$, $-L_2C(=O)OL_6R^{12}$, $-L_2C(=O)OL_4C(=O)OL_2R^{12}$, $-L_2C(=O)OL_4C(=O)R^{12}$, $-L_4C(=O)OL_2C(=O)R^{12}$, $-CF_2C(=O)R^7$, $-CH=CHC(=O)OL_4C(=O)R^{12}$, $-OL_2C(=O)OL_4C(=O)R^{12}$, $-OL_4C(=O)OL_2R^{12}$, $-OL_4C(=O)OL_2C(=O)R^{12}$ or $-L_2C(=O)OL_3R^{12}$;

or when R^3 is H, then R^4 is $-L_2C(=O)OR^7$, $-C(=O)OL_6R^{12}$, $-C(=O)OL_2R^{12}$, $-L_2C(=O)OL_2R^{12}$, $-L_4C(=O)OL_5OH$, $-L_4R^{12}$, $-L_2C(=O)OL_4C(=O)L_2R^{12}$, $-L_2C(=O)OL_6R^{12}$, $-L_2C(=O)OL_4C(=O)OL_2R^{12}$, $-L_2C(=O)OL_4C(=O)R^{12}$, $-L_4C(=O)OL_2C(=O)R^{12}$, $-CF_2C(=O)R^7$, $-CH=CHC(=O)OL_4C(=O)R^{12}$, $-OL_2C(=O)OL_4C(=O)R^{12}$, $-OL_4C(=O)OL_2R^{12}$, $-OL_4C(=O)OL_2C(=O)R^{12}$ or $-L_2C(=O)OL_3R^{12}$;

L_1 is $-(CH_2)_m$;

L_2 is $-(CH_2)_m$;

L_3 is $-(CH_2)_m$;

L_4 is $-(CH_2)_m$;

L_5 is $-(CH_2)_m$;

L_6 is $-(CH_2)_mO(CH_2)_m$;

L_9 is $-(CH_2)_m$;

R^6 is $-C_4-C_6$ alkyl;

R^7 is $-C_1-C_3$ alkyl;

R^9 is L_1OH ;

each R^{11} is independently selected from H or $-C_1-C_3$ alkyl;

R^{12} is

f) $-N(R^{11})_2$;

g) an unsubstituted 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O;

h) a 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O substituted with $=O$;

- i) a 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O substituted with C₁-C₃alkyl or -C(=O)OR⁷;


or

- j) an unsubstituted phenyl;


5 and

each m is independently selected from 1, 2, 3, and 4.

3. The compound of claim 1 or claim 2, wherein the compound of Formula (I) is a compound of Formula (Ia) or Formula (Ib):



Formula (Ia)



Formula (Ib).

4. The compound of any one of claims 1 to 3, wherein,

R¹ is -NHR⁶ or -NHCHR⁶R⁹;

R³ is H, -L₂C(=O)OR⁷, -C(=O)OL₆R¹², -C(=O)OL₂R¹², -L₂C(=O)OL₂R¹², -L₄C(=O)OL₅OH, -L₄R¹², -L₂C(=O)OL₄C(=O)L₂R¹², -L₂C(=O)OL₆R¹², -L₂C(=O)OL₄C(=O)OL₂R¹², -L₂C(=O)OL₄C(=O)R¹², -L₄C(=O)OL₂C(=O)R¹² or -L₂C(=O)OL₃R¹²;

R⁴ is H, -CF₂C(=O)R⁷, -L₄R¹², -CH=CHC(=O)OL₄C(=O)R¹², -OL₂C(=O)OL₄C(=O)R¹², -OL₄C(=O)OL₂R¹², -L₂C(=O)OR⁷, -L₂C(=O)OL₄C(=O)R¹², -OL₄C(=O)OL₂C(=O)R¹² or -L₂C(=O)OL₃R¹²;

where when R⁴ is H, then R³ is -L₂C(=O)OR⁷, -C(=O)OL₆R¹², -C(=O)OL₂R¹², -

L₂C(=O)OL₂R¹², -L₄C(=O)OL₅OH, -L₄R¹², -

L₂C(=O)OL₄C(=O)L₂R¹², -L₂C(=O)OL₆R¹², -

L₂C(=O)OL₄C(=O)OL₂R¹², -L₂C(=O)OL₄C(=O)R¹², -

L₄C(=O)OL₂C(=O)R¹² or -L₂C(=O)OL₃R¹²;

or when R³ is H, then R⁴ is -CF₂C(=O)R⁷, -L₄R¹², -CH=CHC(=O)OL₄C(=O)R¹², -

OL₂C(=O)OL₄C(=O)R¹², -OL₄C(=O)OL₂R¹², -L₂C(=O)OR⁷, -

L₂C(=O)OL₄C(=O)R¹², -OL₄C(=O)OL₂C(=O)R¹² or -

L₂C(=O)OL₃R¹²;

L₁ is -CH₂-;

L₂ is -CH₂- or -CH₂CH₂-;

L₃ is -CH₂CH₂- or -CH₂CH₂CH₂CH₂-;

L₄ is -CH₂-;

L₅ is -CH₂CH₂-;

L_6 is $-(CH_2)_2O(CH_2)_2-$;

L_9 is $-CH_2CH_2CH_2CH_2-$;

R^6 is $-C_4$ alkyl or $-C_5$ alkyl;

R^7 is methyl, ethyl or propyl;

5 R^9 is L_1OH ;

each R^{11} is independently selected from $-C_1-C_3$ alkyl;

R^{12} is

a) $-N(R^{11})_2$;

b) an unsubstituted piperazinyl or an unsubstituted morpholinyl;

10 c) a 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O substituted with $=O$;

d) a piperazinyl substituted with C_1-C_3 alkyl or $-C(=O)OR^7$;

or

e) an unsubstituted phenyl;

15 and

each m is independently selected from 1, 2, 3, and 4.

5. The compound of claim 3, wherein,

R^1 is $-NHR^6$ or $-NHCHR^6R^9$;

20 R^3 is $-L_2C(=O)OR^7$, $-C(=O)OL_6R^{12}$, $-C(=O)OL_2R^{12}$, $-L_2C(=O)OL_2R^{12}$, $-L_4C(=O)OL_5OH$, $-L_4R^{12}$, $-L_2C(=O)OL_4C(=O)L_2R^{12}$, $-L_2C(=O)OL_6R^{12}$, $-L_2C(=O)OL_4C(=O)OL_2R^{12}$, $-L_2C(=O)OL_4C(=O)R^{12}$, $-L_4C(=O)OL_2C(=O)R^{12}$, $-CF_2C(=O)OR^7$, $-C(=O)OR^7$, $-N(R^{11})_2$ or $-L_2C(=O)OL_3R^{12}$;

25 R^4 is $-CF_2C(=O)R^7$, $-L_4R^{12}$, $-CH=CHC(=O)OL_4C(=O)R^{12}$, $-OL_2C(=O)OL_4C(=O)R^{12}$, $-OL_4C(=O)OL_2R^{12}$, $-L_2C(=O)OR^7$, $-L_2C(=O)OL_4C(=O)R^{12}$, $-OL_4C(=O)OL_2C(=O)R^{12}$, $-CF_2C(=O)OR^7$, $-C(=O)OR^7$, $-N(R^{11})_2$ or $-L_2C(=O)OL_3R^{12}$;

L_1 is $-CH_2-$;

L_2 is $-CH_2-$ or $-CH_2CH_2-$;

L_3 is $-CH_2CH_2-$ or $-CH_2CH_2CH_2CH_2-$;

L_4 is $-CH_2-$,

30 L_5 is $-CH_2CH_2-$,

L_6 is $-(CH_2)_2O(CH_2)_2-$;

L_9 is $-CH_2CH_2CH_2CH_2-$;

R^6 is $-C_4$ alkyl or $-C_5$ alkyl;

R^7 is methyl, ethyl or propyl;

35 R^9 is L_1OH ;

each R^{11} is independently selected from $-C_1-C_3$ alkyl;

R^{12} is

- a) $-N(R^{11})_2$;
- b) an unsubstituted piperazinyl or an unsubstituted morpholinyl;
- c) a 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O substituted with $=O$;
- 5 d) a piperazinyl substituted with C_1 - C_3 alkyl or $-C(=O)OR^7$;
- or
- e) an unsubstituted phenyl;

and

each m is independently selected from 1, 2, 3, and 4.

10 6. The compound of claim 3, wherein,

R^1 is $-NHR^6$ or $-NHCHR^6R^9$;

R^3 is $-L_2C(=O)OR^7$, $-C(=O)OL_6R^{12}$, $-C(=O)OL_2R^{12}$, $-L_2C(=O)OL_2R^{12}$, $-L_4C(=O)OL_5OH$, $-L_4R^{12}$, $-L_2C(=O)OL_4C(=O)L_2R^{12}$, $-L_2C(=O)OL_6R^{12}$, $-L_2C(=O)OL_4C(=O)OL_2R^{12}$, $-L_2C(=O)OL_4C(=O)R^{12}$, $-L_4C(=O)OL_2C(=O)R^{12}$ or $-L_2C(=O)OL_3R^{12}$;

15 R^4 is $-CF_2C(=O)R^7$, $-L_4R^{12}$, $-CH=CHC(=O)OL_4C(=O)R^{12}$, $-OL_2C(=O)OL_4C(=O)R^{12}$, $-OL_4C(=O)OL_2R^{12}$, $-L_2C(=O)OR^7$, $-L_2C(=O)OL_4C(=O)R^{12}$, $-OL_4C(=O)OL_2C(=O)R^{12}$ or $-L_2C(=O)OL_3R^{12}$;

L_1 is $-CH_2-$;

L_2 is $-CH_2-$ or $-CH_2CH_2-$;

20 L_3 is $-CH_2CH_2-$ or $-CH_2CH_2CH_2CH_2-$;

L_4 is $-CH_2-$;

L_5 is $-CH_2CH_2-$;

L_6 is $-(CH_2)_2O(CH_2)_2-$;

L_9 is $-CH_2CH_2CH_2CH_2-$;

25 R^6 is $-C_4$ alkyl or $-C_5$ alkyl;

R^7 is methyl, ethyl or propyl;

R^9 is L_1OH ;

each R^{11} is independently selected from $-C_1$ - C_3 alkyl;

R^{12} is

- 30 f) $-N(R^{11})_2$;
- g) an unsubstituted piperazinyl or an unsubstituted morpholinyl;
- h) a 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms independently selected from N and O substituted with $=O$;
- i) a piperazinyl substituted with C_1 - C_3 alkyl or $-C(=O)OR^7$;
- 35 or
- j) an unsubstituted phenyl;

and

each m is independently selected from 1, 2, 3, and 4.

7. The compound of any one of claims 1 to 3, wherein,

R^1 is $-NHR^6$;

R^3 is $-L_2C(=O)OL_4C(=O)R^{12}$ and R^4 is H;

5 or R^3 is H and R^4 is $-L_2C(=O)OL_4C(=O)R^{12}$;

R^6 is $-C_4-C_6$ alkyl;

L_2 is $-(CH_2)_m-$;

L_4 is $-(CH_2)_m-$;

R^{12} is an unsubstituted 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms

10 independently selected from N and O;

and

each m is independently selected from 1, 2, 3, and 4.

8. The compound of any one of claims 1 to 3, wherein,

R^1 is $-NHR^6$;

15 R^3 is $-L_2C(=O)OL_4C(=O)L_2R^{12}$ and R^4 is H;

or R^3 is H and R^4 is $-L_2C(=O)OL_4C(=O)L_2R^{12}$;

R^6 is $-C_4-C_6$ alkyl;

L_2 is $-(CH_2)_m-$;

L_4 is $-(CH_2)_m-$;

20 R^{12} is an unsubstituted 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms

independently selected from N and O;

and

each m is independently selected from 1, 2, 3, and 4.

9. The compound of any one of claims 1 to 3, wherein,

25 R^1 is $-NHR^6$;

R^3 is $-L_2C(=O)OL_4C(=O)R^{12}$ and R^4 is H;

or R^3 is H and R^4 is $-L_2C(=O)OL_4C(=O)R^{12}$;

R^6 is $-C_6$ alkyl;

L_2 is $-CH_2-$ or $-CH_2CH_2-$;

30 L_4 is $-CH_2-$,

and

R^{12} is an unsubstituted piperazinyl or an unsubstituted morpholinyl.

10. The compound of any one of claims 1 to 3, wherein,

R^1 is $-NHR^6$;

35 R^3 is $-L_2C(=O)OL_4C(=O)L_2R^{12}$ and R^4 is H;

or R^3 is H and R^4 is $-L_2C(=O)OL_4C(=O)L_2R^{12}$;

R^6 is $-C_5$ alkyl;

L_2 is $-CH_2-$ or $-CH_2CH_2-$;

L_4 is $-CH_2-$,

and

5 R^{12} is an unsubstituted piperazinyl or an unsubstituted morpholinyl.

11. The compound of any one of claims 1 to 3, wherein,

R^1 is $-NHR^6$ or $-NHCHR^6R^9$;

R^3 is H and R^4 is $-L_4R^{12}$;

or R^3 is $-L_4R^{12}$ and R^4 is H;

10 L_1 is $-(CH_2)_m-$;

L_4 is $-(CH_2)_m-$;

R^6 is $-C_4-C_6$ alkyl;

R^9 is L_1OH ;

R^{12} is an unsubstituted 5-6 membered heterocycloalkyl having 1 to 2 heteroatoms

15 independently selected from N and O;

and

each m is independently selected from 1, 2, 3, and 4.

12. The compound of any one of claims 1 to 3, wherein,

R^1 is $-NHR^6$ or $-NHCHR^6R^9$;

20 R^3 is H and R^4 is $-L_4R^{12}$;

or R^3 is $-L_4R^{12}$ and R^4 is H;

L_1 is $-(CH_2)-$;

L_4 is $-(CH_2)-$;

R^6 is $-C_4$ alkyl or $-C_5$ alkyl;

25 R^9 is L_1OH ,

and

R^{12} is an unsubstituted piperazinyl.

13. The compound of claim 1, wherein the compound is selected from:

30 2-(dimethylamino)ethyl 4-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-3-methoxybenzoate;

2-(2-(dimethylamino)ethoxy)ethyl 4-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-3-methoxybenzoate;

methyl 2-(3-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenyl)acetate;

35 ethyl 3-(3-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenyl)propanoate;

methyl 2-(3-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenyl)-2,2-difluoroacetate;

2-morpholino-2-oxoethyl 2-(3-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenoxy)acetate;

5 2-morpholino-2-oxoethyl 2-(3-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenyl)acetate;

2-morpholino-2-oxoethyl 2-(4-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-3-methoxyphenyl)acetate;

10 2-(morpholin-4-yl)-2-oxoethyl 3-(4-([2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl)-3-methoxyphenyl)propanoate;

(S)-2-morpholino-2-oxoethyl 3-(3-((2-amino-4-((1-hydroxyhexan-2-yl)amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenyl)propanoate;

(S)-2-morpholino-2-oxoethyl 2-(4-((2-amino-4-((1-hydroxyhexan-2-yl)amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-3-methoxyphenyl)acetate;

15 (S)-2-morpholino-2-oxoethyl 2-(3-((2-amino-4-((1-hydroxyhexan-2-yl)amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenyl)acetate;

(S)-2-morpholino-2-oxoethyl 3-(4-((2-amino-4-((1-hydroxyhexan-2-yl)amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-3-methoxyphenyl)propanoate;

20 2-(morpholin-4-yl)-2-oxoethyl (2E)-3-(3-([2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl)-4-methoxyphenyl)prop-2-enoate;

2-(morpholin-4-yl)-2-oxoethyl 3-(3-([2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl)-4-methoxyphenyl)propanoate;

2-(benzyloxy)-2-oxoethyl 2-(4-([2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl)-3-methoxyphenyl)acetate;

25 2-(dipropylcarbamoyl)methyl 2-(4-([2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl)-3-methoxyphenyl)acetate;

2-(dimethylamino)-2-oxoethyl 2-(4-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-3-methoxyphenyl)acetate;

30 2-(4-methylpiperazin-1-yl)ethyl 2-(4-([2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl)-3-methoxyphenyl)acetate;

2-hydroxyethyl 2-(4-([2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl)-3-methoxyphenyl)acetate;

4-(dimethylamino)butyl 2-(4-([2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl)-3-methoxyphenyl)acetate;

35 2-(morpholin-4-yl)ethyl 2-(4-([2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl)-3-methoxyphenyl)acetate;

2-(piperazin-1-yl)ethyl 2-(4-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-3-methoxyphenyl)acetate;

2-(dimethylamino)ethyl 2-(3-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-4-methoxyphenoxy)acetate;

5 2-(piperazin-1-yl)ethyl 2-(3-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-4-methoxyphenoxy)acetate;

2-(morpholin-4-yl)ethyl 2-(3-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-4-methoxyphenoxy)acetate;

10 2-(4-methylpiperazin-1-yl)ethyl 2-(3-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-4-methoxyphenoxy)acetate;

(S)-2-((2-amino-5-(2-methoxy-4-(piperazin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol;

5-(2-methoxy-4-(piperazin-1-ylmethyl)benzyl)-N4-pentyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine;

15 5-(2-methoxy-5-(piperazin-1-ylmethyl)benzyl)-N4-pentyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine;

(S)-2-((2-amino-5-(2-methoxy-5-(piperazin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol, and

5-(5-amino-2-methoxybenzyl)-N4-pentyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine.

20 14. The compound of claim 1, wherein the compound is selected from:

2-morpholino-2-oxoethyl 2-(3-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenoxy)acetate;

2-morpholino-2-oxoethyl 2-(3-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-4-methoxyphenyl)acetate;

25 2-morpholino-2-oxoethyl 2-(4-((2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl)methyl)-3-methoxyphenyl)acetate, and

2-(morpholin-4-yl)-2-oxoethyl 3-(4-{[2-amino-4-(pentylamino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]methyl}-3-methoxyphenyl)propanoate.

15. The compound of claim 1, wherein the compound is selected from:

30 (S)-2-((2-amino-5-(2-methoxy-4-(piperazin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol;

5-(2-methoxy-4-(piperazin-1-ylmethyl)benzyl)-N4-pentyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine;

35 5-(2-methoxy-5-(piperazin-1-ylmethyl)benzyl)-N4-pentyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine;

(S)-2-((2-amino-5-(2-methoxy-5-(piperazin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-yl)amino)hexan-1-ol, and

5-(5-amino-2-methoxybenzyl)-N4-pentyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine.

16. A pharmaceutical composition comprising a therapeutically effective amount of a compound
5 of any one of claims 1-15 and a pharmaceutically acceptable carrier.
17. Use of a compound of any one of claims 1-15 in the manufacture of a medicament for treating a disease or disorder associated with TLR7 activity.
18. The use of claim 17, wherein the disease is an infectious disease, a viral infectious disease, an inflammatory disease, a respiratory disease, a dermatological disease, an autoimmune
10 disease, a cell-proliferative disease or cancer.
19. The use of claim 17, wherein the disease or condition is asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome (ARDS), ulcerative colitis, Crohn's disease, bronchitis, dermatitis, actinic keratosis, basal cell carcinoma, bladder cancer, allergic rhinitis, psoriasis, scleroderma, urticaria, rheumatoid arthritis, multiple
15 sclerosis, cancer, breast cancer, HIV, hepatitis, hepatitis C or lupus.
20. The use of claim 17, wherein the disease or condition is hepatitis B, hepatitis C, colorectal cancer or hepatocellular carcinoma.
21. A compound for use in a method of treating a disease associated with TLR7 receptor activity, wherein the disease is an infectious disease, a viral infectious disease, an
20 inflammatory disease, a respiratory disease, a dermatological disease, an autoimmune disease, a cell-proliferative disease or cancer, and wherein the compound is a compound of any one of claims 1-15.